Redefining the standard of care for low-grade serous ovarian cancer

Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated follo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical advances in hematology & oncology 2024-06, Vol.22 (5), p.205
Main Authors: Manning-Geist, Beryl L, Cantor, Tal, O'Cearbhaill, Róisín E, Grisham, Rachel N
Format: Article
Language:English
Subjects:
Carcinoma, Ovarian Epithelial - pathology
Carcinoma, Ovarian Epithelial - therapy
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - therapy
Female
Humans
Molecular Targeted Therapy
Neoplasm Grading
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Standard of Care
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page 205
container_title Clinical advances in hematology & oncology
container_volume 22
creator Manning-Geist, Beryl L
Cantor, Tal
O'Cearbhaill, Róisín E
Grisham, Rachel N
description Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3061784614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3061784614</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-d523d887158fb50aec1e8e2818d52f8fb9e362c73724256755eeae94e89991ab3</originalsourceid><addsrcrecordid>eNo1j01LxDAYhHNQ3HX1L0iOXgr5bJKjFL9gQRA9l7R5s1bapCat4r834O5pYOZhmDlDWyoFr4gyZIMuc_4kRFDF6gu04VoTySnbouYVHPghDOGAlw_AebHB2eRw9Li3CbCPCY_xpzok60oMKa4Zx2-bBhsKEXpIV-jc2zHD9VF36P3h_q15qvYvj8_N3b6aqaBL5STjTmtFpfadJBZ6ChqYprokvngGeM16xRUTTNZKSgALRoA2xlDb8R26_e-dU_xaIS_tNOQextEGKKtaTmqqtKipKOjNEV27CVw7p2Gy6bc9Hed_-0BShA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3061784614</pqid></control><display><type>article</type><title>Redefining the standard of care for low-grade serous ovarian cancer</title><source>Freely Accessible Journals</source><creator>Manning-Geist, Beryl L ; Cantor, Tal ; O'Cearbhaill, Róisín E ; Grisham, Rachel N</creator><creatorcontrib>Manning-Geist, Beryl L ; Cantor, Tal ; O'Cearbhaill, Róisín E ; Grisham, Rachel N</creatorcontrib><description>Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.</description><identifier>ISSN: 1543-0790</identifier><identifier>PMID: 38805312</identifier><language>eng</language><publisher>United States</publisher><subject>Carcinoma, Ovarian Epithelial - pathology ; Carcinoma, Ovarian Epithelial - therapy ; Cystadenocarcinoma, Serous - diagnosis ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - therapy ; Female ; Humans ; Molecular Targeted Therapy ; Neoplasm Grading ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Standard of Care</subject><ispartof>Clinical advances in hematology &amp; oncology, 2024-06, Vol.22 (5), p.205</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38805312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manning-Geist, Beryl L</creatorcontrib><creatorcontrib>Cantor, Tal</creatorcontrib><creatorcontrib>O'Cearbhaill, Róisín E</creatorcontrib><creatorcontrib>Grisham, Rachel N</creatorcontrib><title>Redefining the standard of care for low-grade serous ovarian cancer</title><title>Clinical advances in hematology &amp; oncology</title><addtitle>Clin Adv Hematol Oncol</addtitle><description>Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.</description><subject>Carcinoma, Ovarian Epithelial - pathology</subject><subject>Carcinoma, Ovarian Epithelial - therapy</subject><subject>Cystadenocarcinoma, Serous - diagnosis</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Grading</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Standard of Care</subject><issn>1543-0790</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo1j01LxDAYhHNQ3HX1L0iOXgr5bJKjFL9gQRA9l7R5s1bapCat4r834O5pYOZhmDlDWyoFr4gyZIMuc_4kRFDF6gu04VoTySnbouYVHPghDOGAlw_AebHB2eRw9Li3CbCPCY_xpzok60oMKa4Zx2-bBhsKEXpIV-jc2zHD9VF36P3h_q15qvYvj8_N3b6aqaBL5STjTmtFpfadJBZ6ChqYprokvngGeM16xRUTTNZKSgALRoA2xlDb8R26_e-dU_xaIS_tNOQextEGKKtaTmqqtKipKOjNEV27CVw7p2Gy6bc9Hed_-0BShA</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Manning-Geist, Beryl L</creator><creator>Cantor, Tal</creator><creator>O'Cearbhaill, Róisín E</creator><creator>Grisham, Rachel N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202406</creationdate><title>Redefining the standard of care for low-grade serous ovarian cancer</title><author>Manning-Geist, Beryl L ; Cantor, Tal ; O'Cearbhaill, Róisín E ; Grisham, Rachel N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-d523d887158fb50aec1e8e2818d52f8fb9e362c73724256755eeae94e89991ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Carcinoma, Ovarian Epithelial - pathology</topic><topic>Carcinoma, Ovarian Epithelial - therapy</topic><topic>Cystadenocarcinoma, Serous - diagnosis</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Grading</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Standard of Care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manning-Geist, Beryl L</creatorcontrib><creatorcontrib>Cantor, Tal</creatorcontrib><creatorcontrib>O'Cearbhaill, Róisín E</creatorcontrib><creatorcontrib>Grisham, Rachel N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical advances in hematology &amp; oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manning-Geist, Beryl L</au><au>Cantor, Tal</au><au>O'Cearbhaill, Róisín E</au><au>Grisham, Rachel N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Redefining the standard of care for low-grade serous ovarian cancer</atitle><jtitle>Clinical advances in hematology &amp; oncology</jtitle><addtitle>Clin Adv Hematol Oncol</addtitle><date>2024-06</date><risdate>2024</risdate><volume>22</volume><issue>5</issue><spage>205</spage><pages>205-</pages><issn>1543-0790</issn><abstract>Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.</abstract><cop>United States</cop><pmid>38805312</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1543-0790
ispartof Clinical advances in hematology & oncology, 2024-06, Vol.22 (5), p.205
issn 1543-0790
language eng
recordid cdi_proquest_miscellaneous_3061784614
source Freely Accessible Journals
subjects Carcinoma, Ovarian Epithelial - pathology
Carcinoma, Ovarian Epithelial - therapy
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - therapy
Female
Humans
Molecular Targeted Therapy
Neoplasm Grading
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Standard of Care
title Redefining the standard of care for low-grade serous ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T00%3A17%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Redefining%20the%20standard%20of%20care%20for%20low-grade%20serous%20ovarian%20cancer&rft.jtitle=Clinical%20advances%20in%20hematology%20&%20oncology&rft.au=Manning-Geist,%20Beryl%20L&rft.date=2024-06&rft.volume=22&rft.issue=5&rft.spage=205&rft.pages=205-&rft.issn=1543-0790&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E3061784614%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p141t-d523d887158fb50aec1e8e2818d52f8fb9e362c73724256755eeae94e89991ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3061784614&rft_id=info:pmid/38805312&rfr_iscdi=true